title: Expanding targeted therapies for NSCLC.
abstract: The targeted therapies dabrafenib and neratinib are being tested separately in subsets of patients with BRAF- and HER2-mutant non-small cell lung cancer. While dabrafenib shows some promise, the preliminary results for neratinib with or without temsirolimus are insufficient to determine whether patients may benefit.
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D058990:Molecular Targeted Therapy; D009154:Mutation